Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States
This is one of the largest studies evaluating the use of tofacitinib in pediatric IBD in the United States. Our results demonstrate that tofacitinib is an effective treatment for these patients.
Authors
- Nancy McGreal
- Jeanne Tung
- Jessica Murphy (ORCID: https://orcid.org/0000-0003-1954-3470)
- J Moses (ORCID: https://orcid.org/0000-0002-5366-7816)
- Denise Young
- Mallory Chavannes (ORCID: https://orcid.org/0000-0001-8787-4891)
- Jennifer Dotson
- Erin Crawford
- Brad Pasternak
- Erica Chang
- Sandra C. Kim
Institutions
- Arkansas Children's Hospital (US)
- Cleveland Clinic (US)
- Lucile Packard Children's Hospital (US)
- Children's Hospital of Los Angeles (US)
- University Hospitals of Cleveland (US)
- University Hospitals Cleveland Medical Center (US)
- Phoenix Children's Hospital (US)
- Duke Medical Center (US)
- Children's Hospital of Pittsburgh (US)
- Rainbow Babies & Children's Hospital (US)
- Case Western Reserve University (US)
- University of Oklahoma (US)
Publication Details
- Journal
- Journal of Pediatric Gastroenterology and Nutrition
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1002/jpn3.70381
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00